Table 5

TUNA vs. TURP: results of meta-analysis of variables of efficacy.

Variable

Studies (No. patients)

TUNA

Difference in means (% improvement)

TURP

Difference in means (% improvement)

TUNA vs. TURP

Difference in means (95% CI), P value


Symptom score


3 months

350,53,56 (384)

-12.49 (57%)

-13.85 (64 %)

1.33 (-.81,3.47), .22

1 year

452–54,57 (427)

-12.09 (55%)

-15.48 (71%)

3.69 (2.09, 5.29), .00

2 years

352,54,57 (368)

-10.42 (48%)

-14.83 (68%)

4.72 (3.77, 5.69), .00

3 years

252,54 (273)

-9.83 (45%)

-14.63 (67%)

4.82 (4.25, 5.39), .00

4 years

154 (121)

-10.80 (50%)

-16.50 (76%)

5.70 (4.67, 6.73), .00

5 years

154 (121)

-13.30 (61%)

-13.30 (61%)

0 (-0.99, 0.99), 1.0


Quality of life score


3 months

350,53,56 (277)

-4.47 (54%)

-3.65 (47%)

-0.40 (-1.25, 0.45), .35

1 year

352–54 (332)

-4.05 (49%)

-4.34 (56%)

0.63 (0.12, 1.15), .01

2 years

252,54 (273)

-3.90 (47%)

-5.67 (74%)

1.69 (-1.05, 4.44), .22

3 years

252,54 (273)

-4.17 (50%)

-5.18 (67%)

1.02 (0.14, 1.90), .02

4 years

154 (121)

-6.6 (80%)

-8.90 (116%)

2.3 (1.84, 2.76), .00

5 years

154 (121)

-8.0 (96%)

-8.60 (112%)

0.6 (0.21, 0.99), .00


Qmax (mL/s)


3 months

350,53,56 (277)

4.85 (57%)

11.37 (148%)

-6.48 (-7.29, -5.68), .00

1 year

452–54,57 (375)

6.49 (76%)

12.23 (160%)

-5.9 (-7.73, -4.08), 00

2 years

450,54,57,58 (430)

4.55 (53%)

12.17 (159%)

-7.93 (-11.1, -4.77), .00

3 years

252,54 (273)

5.6 (66%)

10.80 (141%)

-5.32 (-6.78, -3.85), .00

4 years

154 (121)

2.9 (34%)

10.10 (132%)

-7.2 (-7.99, -6.4), .00

5 years

154 (121)

2.6 (30%)

9.8 (127%)

-7.2 (-7.93, -6.47), .00


PVR (ml)


3 months

350,53,56 (277)

-27.76 (31%)

-44.66 (44%)

23.82 (-19.35, 66.97), .28

1 year

353,54,57 (223)

-21.92 (24%)

-52.42 (51%)

24.97 (20.90, 29.05), .00

2 years

354,57,58 (278)

-27.58 (31%)

-69.24 (68%)

35.8 (25.00, 46.61), .00

5 years

154 (121)

-31.40 (35%)

-54.50 (53%)

23.1 (12.16, 43.04), .00


PdetQmax (cm of water)


6 months

251,58 (235)

-20.52 (27%)

-32.4 (45%)

13.12 (0.6, 25.65), .04

2 years

158 (114)

-28.56 (38%)

-42 (58%)

13.44 (11.6,15.27), .00


No. Abrams-Griffiths


6 months

151 (121)

-24 (39%)

-47.40 (81%)

23.4 (20.7, 26.2), .00


Prostatic size


3 months

250,58 (235)

-2.66 (7%)

-12.98 (34%)

10.13 (-7.02,27.3), .02

1 year

150 (121)

-0.9 (2.4%)

-5.5 (17%)

6.4 (4.8,7.96), .00

2 years

253,58 (173)

-6.46 (15%)

-12.78 (34%)

5.52 (-2.7,13.75), .19


Random effects model. Results are expressed as difference of means and percentage of improvement versus baseline. Abbreviations: CI denotes confidence interval. Qmax denotes maximum urinary flow rate. PVR: Post-void residual volume.

Bouza et al. BMC Urology 2006 6:14   doi:10.1186/1471-2490-6-14

Open Data